Brief: Epigenomics Places Mandatory Convertible Bonds Of Total EUR 16.5 Mln
13/09/2021 13:35
Sept 13 (Reuters) - EPIGENOMICS AG ECXn.DE :
* PLACES MAXIMUM NUMBER OF MANDATORY CONVERTIBLE BONDS WITH
A
TOTAL VOLUME OF EUR 16.5 MLN
* GROSS PROCEEDS FROM ISSUANCE OF MANDATORY CONVERTIBLE BOND
AMOUNT TO EUR 16.5 MLN
* PLANS TO USE PROCEEDS TO FINANCE ITS OPERATIONS, IN
PARTICULAR
FURTHER DEVELOPMENT OF BLOOD-BASED COLORECTAL CANCER SCREENING
TEST EPI PROCOLON NEXT-GEN
* TO CONDUCT A CLINICAL STUDY IN U.S.A., WHICH IS REQUIRED
TO
OBTAIN APPROVAL FOR TEST BY U.S. FOOD AND DRUG ADMINISTRATION
(FDA)
Source text for Eikon: ID:nEQ716KK6a
Further company coverage: ECXn.DE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Epigenomics AG
See all newsU.S. FDA advisers back approval for Guardant's blood-based cancer test (updated)
U.S. FDA advisers back approval for Guardant's cancer test
Brief: Epigenomics Says Closing Of Agreement On The Acquisition Of Almost All Assets And Adjustment Of Guidance For 2023
Brief: Epigenomics AG Says It Entered Into Agreement On The Acquisition Of Almost All Assets With New Day Diagnostics LLC
Brief: Epigenomics Says Chief Scientific Officer Andrew Lukowiak Resigns